| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_148b5925b5858eb0038da3d5196e361f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate |
2013-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c20ef7420ea29e8b4daee20d17a38eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efc64386f815b047dd57daf3728385b9 |
| publicationDate |
2013-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2013137839-A1 |
| titleOfInvention |
Tablet formulation comprising dapagliflozin and extended release metformin |
| abstract |
The present invention is related to a combination formulation coated with dapagliflozin on the extended-release core tablet comprising metformin hydrochloride. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020009352-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106924208-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115414347-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115414347-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102369679-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023136797-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022225489-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190038283-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017114227-A1 |
| priorityDate |
2012-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |